Clinical trials: Giant Cells Arteritis
Giant Cell Arteritis
Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL)
Giant Cell Arteritis (GCA) causes inflammation and narrowing of blood vessels and can cause blindness in one third of patients. It is important that a prompt, accurate diagnosis of GCA is made and treatment given as steroids for…
- Trial name
- TABUL (NCT00974883)
- Testing
- Ultrasound of temporal and axillary arteries, Temporal artery biopsy
- Where
- 27 sites in Germany, Ireland and 3 more
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Systemic Vasculitis, Spondylarthropathies
Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
The purpose of HZ-REUMA study is explore vaccine response and protection against shingles (herpes zoster, HZ) after vaccination with two doses of Shingrix in immunosuppressed patients with inflammatory rheumatic diseases (IRD)…
- Conditions
- Systemic Vasculitis, Spondylarthropathies, Psoriatic Arthritis, Scleroderma
- Trial name
- HZ-REUMA (NCT06763783)
- Testing
- Shingrix, vaccination with 2 doses of Shingrix vaccine
- Where
- Sweden
- Volunteers
- 240 people
- Sponsor
- Region Skane
Giant Cell Arteritis
Prospective Follow-up Study of the Aortic Diameter in Patients With Giant Cell Arteritis
Giant cell arteritis (GCA) is the most frequent vasculitis in patients above 50 years of age. The disease has limited mortality, mostly due to the development of aortic aneurysms, leading to dissection and rupture.
- Trial name
- ATACT (NCT01588483)
- Where
- Belgium
- Volunteers
- 163 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Giant Cell Arteritis
KPL-301 for Subjects With Giant Cell Arteritis
The primary objective of the study is to evaluate the efficacy of mavrilimumab (KPL-301) versus placebo, co-administered with a 26-week corticosteroid taper, for maintaining sustained remission for 26 weeks in subjects with new…
- Trial name
- NCT03827018
- Testing
- mavrilimumab, prednisone
- Where
- 49 sites in United States, Australia and 13 more
- Volunteers
- 70 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Giant Cell Arteritis, Vasculitis
Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
The aim of this project is to prospectively evaluate the diagnostic accuracy of different imaging tools in specific giant cell arteritis disease subsets before and after treatment initiation.
- Trial name
- NCT03765424
- Testing
- Ultrasound
- Volunteers
- 101 people
- Sponsor
- University of Aarhus
Temporal Arteritis
MRI Superficial Temporal Artery
Repeat MRI of the Superficial temporal Artery in 5 volunteers
- Trial name
- NCT00188448
- Testing
- MRI
- Where
- Canada
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy
Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis
Giant cell arteritis (GCA) is an inflammation of the blood vessels. A dangerous complication is sudden vision loss due to insufficient blood supply to the optic nerve.
- Conditions
- Giant Cell Arteritis (GCA), Ischemic Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy
- Trial name
- VISION-GCA (NCT07206238)
- Testing
- Positron Emission Tomography / Magnetic Resonance Imaging
- Where
- Denmark
- Volunteers
- 122 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Giant Cell Arteritis
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)
This is a multicenter, interventional, open-label, long-term extension study of Study WA28119 (NCT01791153) to evaluate the long-term safety of SC tocilizumab in participants with GCA who subsequently have flare or persisting…
- Trial name
- NCT03202368
- Testing
- Tocilizumab
- Where
- 3 sites in France
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Giant Cell Arteritis
Comparison of 22Mhz and 18Mhz High-frequency Probes for the Ultrasound Study of Temporal Arteries in Patients Suspected of Having Giant Cell Arteritis
Evaluation of the structural features of temporal arteritis using two frequencies probes: 18 and 22Mhz.
- Trial name
- ECHORTON (NCT04204512)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Brest
Giant Cell Arteritis, Temporal Arteritis
Ustekinumab for the Treatment of Giant Cell Arteritis
The purpose of this study is to determine whether ustekinumab is effective in the treatment of Giant Cell Arteritis (GCA)
- Conditions
- Giant Cell Arteritis, Temporal Arteritis, Horton's Disease
- Trial name
- UGCA (NCT02955147)
- Testing
- Ustekinumab, Prednisone
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Horton Disease
Chewing Gum Test for the Diagnosis of Giant Cell Arteritis (Horton's Disease) - ChewingHort
It is hypothesized that chewing-gums may be a useful test to unmask jaws intermittent claudication in order to enhance the diagnosis of Giant Cell Arteritis (GCA).
- Trial name
- ChewingHort (NCT04010097)
- Testing
- chewing gum
- Where
- 6 sites in France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University Hospital, Limoges
Giant Cell Arteritis
Tocilizumab Plus a Short Prednisone Taper for GCA
This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.
- Trial name
- NCT03726749
- Testing
- Tocilizumab, Prednisone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Giant Cell Arteritis
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
Giant cell arteritis (GCA), also known as Horton's disease, is an inflammatory arteritis of the large and medium-sized arteries, with an estimated incidence of 17.8/100,000 in people over 50.
- Trial name
- EvHortim (NCT06004154)
- Testing
- Injected cerebral MRI angiography and ultrasound of the superior aortic trunks, temporal and axillary arteries
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Horton's Disease
Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease
Giant cell arteritis (GCA) is the most frequent vascularitis after 50 years of age The investigators recently showed that GCA was accompanied by an elevation in Th1 and Th17 response [1].
- Trial name
- ACG et TREG (NCT02857192)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 41 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Giant Cell Arteritis
Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis
The standard treatment for Giant Cell arteritis (GCA) is Glucocorticoids(GC), even if GC-related adverse events are commonly occuring. Therefore, other practises for reducing relapses and cumulative GC-doses are needed.
- Trial name
- MTXinGCA (NCT05623592)
- Testing
- Methotrexate, Sodium chloride
- Where
- Germany
- Volunteers
- 52 people
- Sponsor
- University of Bonn
Giant Cell Arteritis
Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
Corticosteroid therapy has always been the standard treatment for giant cell arteritis (GCA), with very good initial clinical efficacy but a high relapse rate when it declines.
- Trial name
- CORTODOSE (NCT04012905)
- Testing
- Corticosteroids for Systemic Use
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Caen
Giant Cell Arteritis, Temporal Arteritis
Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA
Giant cell arteritis (GCA) is an inflammatory disease of large and medium arteries that can cause irreversible vision loss. Glucocorticoids (GCs) rapidly suppress inflammation, but diagnostic imaging tests such as temporal artery…
- Conditions
- Giant Cell Arteritis, Temporal Arteritis, Optic Nerve Diseases, Diagnosis
- Trial name
- SONIC-TIME (NCT07508514)
- Testing
- Optic Nerve Sheath Ultrasound, Temporal artery ultrasound, Bloodwork : CRP and ESR
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis
One-Time DNA Study for Vasculitis
The purpose of this study is to identify genes that increase the risk of developing vasculitis, a group of severe diseases that feature inflammation of blood vessels.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis
- Trial name
- NCT01241305
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 1,000 people
- Sponsor
- University of Pennsylvania
Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS)
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication.
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis
- Trial name
- LoDoNaVasc (NCT03482479)
- Testing
- Naltrexone Hydrochloride
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Pennsylvania
Vasculitis, Diagnoses Disease
CXCR4-PET/CT for Diagnosing Giant Cell Arteritis
Giant cell arteritis (GCA) is the most common vasculitis in the elderly. Accurate diagnosis is of utmost importance in order to then initiate the necessary immunosuppressive therapy.
- Trial name
- NCT05604482
- Testing
- CXCR4-PET
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Matthias Fröhlich